EXPO CEO Catherine Corrigan Exercises Options and Sells Shares
Catherine Corrigan, President & CEO and Director of Exponent Inc (EXPO), reported option exercises and related stock sales on 08/14/2025.
Rhea-AI Filing Summary
Catherine Corrigan, President & CEO and Director of Exponent Inc (EXPO), reported option exercises and related stock sales on 08/14/2025. She exercised two non-qualified stock option tranches: 3,226 options at a $25.405 exercise price and 2,380 options at $29.05. Concurrent with exercise, shares were sold: 3,226 shares at $70.9347 and 1,670 shares at $71.3816; the filing states the sale was to cover the option exercise price and taxes. After these transactions her beneficial ownership of common stock was reported as 82,052 shares.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine option exercises and sell-to-cover transactions by the CEO, no material change to ownership.
The filing documents standard option exercises and sell-to-cover dispositions by the CEO. Exercises increased underlying shares acquired (5,606 total) but reported sales reduced immediate holdings, resulting in 82,052 shares beneficially owned after transactions. Prices show a substantial premium of exercised/strike prices to sale prices, reflecting appreciation since option grant. This is a commonplace liquidity/tax management move and does not by itself signal a change in corporate outlook.
TL;DR: Transaction follows normal insider reporting and Rule 10b5-1 plan disclosure; governance appears compliant.
The Form 4 indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1 affirmative defense, and includes an explanation that shares were sold to cover exercise price and taxes. The report is signed on behalf of the reporting person and includes required details: option strikes, exercisable schedule, and resulting beneficial ownership. Documentation in the filing meets standard disclosure expectations for insider option exercises.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 3,226 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 2,380 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,226 | $25.405 | $82K |
| Sale | Common Stock | 3,226 | $70.9347 | $229K |
| Exercise | Common Stock | 2,380 | $29.05 | $69K |
| Sale | Common Stock | 1,670 | $71.3816 | $119K |
Footnotes (3)
- F1. Stock sale was to cover the option exercise price and taxes.
- F2. The stock option becomes exercisable in four equal annual installments.
- F3. Not applicable.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did EXPO CEO Catherine Corrigan report on Form 4 filed for 08/14/2025?
What were the exercise and sale prices reported in the EXPO Form 4?
Was the transaction part of a 10b5-1 plan according to the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.